m+Medelevator.RU
← Поиск публикаций
Colloids and surfaces. B, Biointerfaces · 2026

Structural, microstructural and surface properties of colloidal Pt@TiO₂-rGO nanocomposite for biomedical applications.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Gahbiche Omar, Ajjel Ridha, Chiba Elaa, Marzouki Riadh, Mezni Amine

Аннотация

This study reports a multifunctional Pt@TiO₂-rGO nanocomposite synthesized via a one-step solvothermal method and further PEGylated to enhance colloidal stability for biomedical applications. The nanocomposite integrates ultrasound-activated sonodynamic therapy (SDT), sono-thermal effects, radiotherapy dose enhancement, and enzyme-mimetic catalytic activity. Under ultrasound irradiation (1 MHz, 1 W·cm-2), the nanocomposite exhibits high sonocatalytic activity, achieving approximately 85% methylene blue degradation within 30 min, consistent with ROS-mediated activity under ultrasound and catalytic conditions. Sono-thermal studies (3 MHz, 2 W·cm-2) demonstrate a temperature increase up to 52.3 °C, highlighting its potential for localized thermal therapy. In radiotherapy experiments, Pt@TiO₂-rGO exhibited dose enhancement values reaching approximately 11.62% under 12 MeV electron irradiation, indicating its potential as a radiosensitizing platform for superficial treatment conditions. Additionally, the nanocomposite exhibits peroxidase-like activity through H₂O₂-mediated oxidation of OPD and catalase-like activity via H₂O₂ decomposition, supporting its role as a multifunctional nanozyme. These findings demonstrate that the Pt@TiO₂-rGO nanocomposite represents a versatile platform combining sonodynamic, thermal, catalytic, and radiotherapy-related functionalities. This integrated behavior highlights its potential for multimodal cancer therapy, although further biological and in vivo investigations are required to validate its clinical applicability.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты